Christopher B. Hopson

1.9k total citations
13 papers, 514 citations indexed

About

Christopher B. Hopson is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Christopher B. Hopson has authored 13 papers receiving a total of 514 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Oncology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Christopher B. Hopson's work include Monoclonal and Polyclonal Antibodies Research (5 papers), Platelet Disorders and Treatments (4 papers) and Glycosylation and Glycoproteins Research (3 papers). Christopher B. Hopson is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (5 papers), Platelet Disorders and Treatments (4 papers) and Glycosylation and Glycoproteins Research (3 papers). Christopher B. Hopson collaborates with scholars based in United States, United Kingdom and France. Christopher B. Hopson's co-authors include Connie L. Erickson‐Miller, Jon Rosen, Kevin J. Duffy, Elizabeth I. Valoret, Shin‐Shay Tian, Evelyne Delorme, Stephen G. Miller, Juan I. Luengo, Teresa S. Sellers and J.M. Jenkins and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Christopher B. Hopson

11 papers receiving 500 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher B. Hopson United States	8	370	109	92	64	60	13	514
Qingshu Zeng China	9	348 0.9×	77 0.7×	62 0.7×	75 1.2×	93 1.6×	23	451
Minna Voigtlaender Germany	9	112 0.3×	120 1.1×	55 0.6×	31 0.5×	34 0.6×	22	341
J Marty Australia	7	243 0.7×	101 0.9×	82 0.9×	34 0.5×	11 0.2×	7	395
Assunta Melaccio Italy	13	222 0.6×	242 2.2×	52 0.6×	103 1.6×	33 0.6×	29	473
Julie A. Di Paolo United States	9	116 0.3×	100 0.9×	131 1.4×	168 2.6×	76 1.3×	17	521
Normann Steiner Austria	14	180 0.5×	219 2.0×	98 1.1×	54 0.8×	108 1.8×	55	471
R D Clutterbuck United Kingdom	13	133 0.4×	205 1.9×	32 0.3×	49 0.8×	32 0.5×	24	484
Stephen J. Harding United Kingdom	11	230 0.6×	236 2.2×	75 0.8×	52 0.8×	26 0.4×	18	405
Paul M. Diderichsen United States	10	90 0.2×	101 0.9×	79 0.9×	45 0.7×	19 0.3×	38	341
Xiaoying Qi China	13	311 0.8×	346 3.2×	86 0.9×	23 0.4×	44 0.7×	31	515

Countries citing papers authored by Christopher B. Hopson

Since Specialization

Citations

This map shows the geographic impact of Christopher B. Hopson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher B. Hopson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher B. Hopson more than expected).

Fields of papers citing papers by Christopher B. Hopson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher B. Hopson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher B. Hopson. The network helps show where Christopher B. Hopson may publish in the future.

Co-authorship network of co-authors of Christopher B. Hopson

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher B. Hopson. A scholar is included among the top collaborators of Christopher B. Hopson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher B. Hopson. Christopher B. Hopson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Waight, Jeremy D., Meixia Bi, David Kilian, et al.. (2020). Abstract 2220: Non-clinical tumor models reveal broad combination potential of ICOS agonist antibodies. Cancer Research. 80(16_Supplement). 2220–2220.

de, Rocío Montes, Sabyasachi Bhattacharya, Laura Seestaller‐Wehr, et al.. (2019). PF558 THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY. HemaSphere. 3(S1). 231–231. 14 indexed citations

Bhattacharya, Sabyasachi, Paul Bojczuk, David Kilian, et al.. (2018). Evaluation of OX40 receptor density, influence of IgG Isotype and dosing paradigm in anti-OX40-mediated efficacy and biomarker responses with PD-1 blockade. Annals of Oncology. 29. viii424–viii425.

Bhattacharya, Sabyasachi, Christopher Matheny, Niranjan Yanamandra, et al.. (2018). Synergy of TLR4 agonist GSK1795091, an innate immune activator, with agonistic antibody against co-stimulatory immune checkpoint molecule OX40 in cancer immunotherapy.. Journal of Clinical Oncology. 36(15_suppl). 12055–12055. 8 indexed citations

Yadavilli, Sapna, Tianqian Zhang, Ashleigh Hahn, et al.. (2017). Abstract 1637: ICOS agonism induces potent immune activation and anti-tumor response in non-clinical models. Cancer Research. 77(13_Supplement). 1637–1637. 2 indexed citations

Hopson, Christopher B., Alfred Hahn, Katherine Sully, et al.. (2014). 300 Preclinical pharmacologic characterization of GSK2849330, a monoclonal AccretaMab® antibody with optimized ADCC and CDC activity directed against HER3. European Journal of Cancer. 50. 98–99. 9 indexed citations

Erickson‐Miller, Connie L., Evelyne Delorme, Shin‐Shay Tian, et al.. (2008). Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist. Stem Cells. 27(2). 424–430. 221 indexed citations

Erickson‐Miller, Connie L., Caretha L. Creasy, Christopher B. Hopson, et al.. (2007). GSK626616: A DYRK3 Inhibitor as a Potential New Therapy for the Treatment of Anemia.. Blood. 110(11). 510–510. 5 indexed citations

Safonov, Igor G., Dirk A. Heerding, Richard M. Keenan, et al.. (2006). New benzimidazoles as thrombopoietin receptor agonists. Bioorganic & Medicinal Chemistry Letters. 16(5). 1212–1216. 37 indexed citations

10.

Erickson‐Miller, Connie L., Shin‐Shay Tian, Christopher B. Hopson, et al.. (2005). Species specificity and receptor domain interaction of a small molecule Tpo receptor agonist, SB-497115. Cancer Research. 65. 1163–1163. 2 indexed citations

11.

Erickson‐Miller, Connie L., Evelyne Delorme, Shin‐Shay Tian, et al.. (2005). Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Experimental Hematology. 33(1). 85–93. 160 indexed citations

12.

Erickson‐Miller, Connie L., Leslie Giampa, Christopher B. Hopson, et al.. (2004). Biological Activity and Selectivity for Tpo Receptor of the Orally Bioavailable, Small Molecule Tpo Receptor Agonist, SB-497115.. Blood. 104(11). 2912–2912. 27 indexed citations

13.

Erickson‐Miller, Connie L., Sylvie Freeman, Christopher B. Hopson, et al.. (2003). Characterization of Siglec-5 (CD170) expression and functional activity of anti–Siglec-5 antibodies on human phagocytes. Experimental Hematology. 31(5). 382–388. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact